In addition, the combination therapy also enhanced PD-L1 expression and the levels of tumor immune infiltration in lung cancer.47 These results provide a method for NSCLC therapy, but further clinical evaluation of the combination of a JAK/STAT inhibitor with virotherapy or immunotherapy needs to be carried out. This evidence concerns the gene SOAT1 and neoplasm.